IL285197A - Methods and preparations for the treatment of sleep apnea - Google Patents
Methods and preparations for the treatment of sleep apneaInfo
- Publication number
- IL285197A IL285197A IL285197A IL28519721A IL285197A IL 285197 A IL285197 A IL 285197A IL 285197 A IL285197 A IL 285197A IL 28519721 A IL28519721 A IL 28519721A IL 285197 A IL285197 A IL 285197A
- Authority
- IL
- Israel
- Prior art keywords
- compositions
- methods
- sleep apnea
- treating sleep
- treating
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 201000002859 sleep apnea Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962803223P | 2019-02-08 | 2019-02-08 | |
| PCT/US2020/017323 WO2020163785A1 (en) | 2019-02-08 | 2020-02-07 | Methods and compositions for treating sleep apnea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL285197A true IL285197A (en) | 2021-09-30 |
Family
ID=71947080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL285197A IL285197A (en) | 2019-02-08 | 2021-07-28 | Methods and preparations for the treatment of sleep apnea |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US12558327B2 (https=) |
| EP (2) | EP4635514A3 (https=) |
| JP (2) | JP7705348B2 (https=) |
| KR (1) | KR20210125507A (https=) |
| CN (2) | CN118557736A (https=) |
| AU (2) | AU2020219809B2 (https=) |
| BR (1) | BR112021015600A2 (https=) |
| CA (1) | CA3129270A1 (https=) |
| EA (1) | EA202192202A1 (https=) |
| ES (1) | ES3049086T3 (https=) |
| IL (1) | IL285197A (https=) |
| MX (2) | MX2021009407A (https=) |
| MY (1) | MY210043A (https=) |
| PH (1) | PH12021551850A1 (https=) |
| SG (1) | SG11202108225QA (https=) |
| UA (1) | UA130366C2 (https=) |
| WO (1) | WO2020163785A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3746126B1 (en) | 2018-01-30 | 2024-07-31 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea or simple snoring |
| EP4635514A3 (en) | 2019-02-08 | 2025-12-24 | The Brigham & Women's Hospital, Inc. | Methods and compositions for treating sleep apnea |
| GEAP202416361A (en) * | 2021-03-24 | 2024-04-25 | Apnimed Inc Delaware | Methods and compositions for treating sleep apnea |
| KR20240021920A (ko) * | 2021-06-17 | 2024-02-19 | 애프니메드, 인코포레이티드 (델라웨어) | 수면 무호흡증을 치료하기 위한 노르에피네프린 재흡수 억제제 |
| US20250302814A1 (en) * | 2022-05-13 | 2025-10-02 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
| CN119789855A (zh) * | 2022-09-02 | 2025-04-08 | 爱普宁公司(特拉华) | 治疗睡眠呼吸暂停的方法和组合物 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| EP1191930A2 (en) | 1999-05-20 | 2002-04-03 | Sepracor Inc. | Methods for treatment of asthma using s-oxybutynin |
| PT1257277E (pt) | 2000-02-24 | 2005-09-30 | Pharmacia & Upjohn Co Llc | Novas combinacoes de farmacos |
| US20020155113A1 (en) | 2001-03-13 | 2002-10-24 | Miyoung Chun | Methods for treating or preventing cardiovascular disorders by modulating metalloprotease function |
| US20030185882A1 (en) | 2001-11-06 | 2003-10-02 | Vergez Juan A. | Pharmaceutical compositions containing oxybutynin |
| US20040235925A1 (en) | 2002-12-17 | 2004-11-25 | Pharmacia Corporation | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
| CA2566154A1 (en) | 2004-05-27 | 2005-12-08 | Warner-Lambert Company Llc | Combination of atomoxetine and a 5t1a receptor agonist for treating adhd and other disorders |
| US20060039867A1 (en) * | 2004-08-20 | 2006-02-23 | Cypress Bioscience, Inc. | Method for treating sleep-related breathing disorders with setiptiline |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| WO2006055854A2 (en) * | 2004-11-17 | 2006-05-26 | Cypress Bioscience, Inc. | Methods for reducing the side effects associated with mirtazapine treatment |
| KR20070087678A (ko) | 2004-12-20 | 2007-08-28 | 컬리지움 파마슈티칼, 인코포레이티드 | 수면 장애용 약제 조성물 |
| FR2889811B1 (fr) | 2005-08-19 | 2009-10-09 | Sanofi Aventis Sa | Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique. |
| ES2610508T3 (es) | 2006-11-22 | 2017-04-27 | Clinical Research Associates, Llc | Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo |
| WO2008122019A1 (en) | 2007-04-02 | 2008-10-09 | Cypress Biosciences, Inc. | Improving the tolerability of both mirtazapine and reboxetine by using them in combination |
| EP2455076A1 (en) * | 2007-04-09 | 2012-05-23 | Sepracor Inc. | Compositions comprising desvenlafaxine for use in treating sleep-related breathing disorders |
| EP2167096A4 (en) * | 2007-06-13 | 2010-07-14 | Cypress Bioscience Inc | IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM |
| CN101925349A (zh) * | 2007-12-21 | 2010-12-22 | 欧兰德股份有限公司 | 替马西泮的口腔崩解片组合物 |
| US20100204058A1 (en) | 2009-01-28 | 2010-08-12 | Howard Yuan-Hao Chang | Profiling for Determination of Response to Treatment for Inflammatory Disease |
| CA2825309C (en) | 2011-01-28 | 2019-10-01 | Pfantastic Medical Research Institute, Llc | Pyridostigmine for the treatment of obstructive sleep apnea |
| WO2016062279A1 (zh) | 2014-10-24 | 2016-04-28 | 朗齐生物医学股份有限公司 | 苹果酸丙氯陪拉辛锭用于制备治疗癌症药物的用途 |
| DK3288946T3 (da) * | 2015-04-27 | 2019-11-25 | Arena Pharm Inc | 5-ht2c-receptoragonister og sammensætninger og anvendelsesfremgangsmåder |
| WO2016201373A1 (en) | 2015-06-12 | 2016-12-15 | Axovant Sciences Ltd. | Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder |
| ES2925951T3 (es) | 2015-07-22 | 2022-10-20 | John Hsu | Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso |
| AU2018260666B2 (en) | 2017-04-28 | 2022-07-21 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treating sleep apnea |
| EP3746126B1 (en) | 2018-01-30 | 2024-07-31 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea or simple snoring |
| EP4635514A3 (en) | 2019-02-08 | 2025-12-24 | The Brigham & Women's Hospital, Inc. | Methods and compositions for treating sleep apnea |
-
2020
- 2020-02-07 EP EP25200289.4A patent/EP4635514A3/en active Pending
- 2020-02-07 KR KR1020217027063A patent/KR20210125507A/ko active Pending
- 2020-02-07 CN CN202410525932.1A patent/CN118557736A/zh active Pending
- 2020-02-07 BR BR112021015600-3A patent/BR112021015600A2/pt unknown
- 2020-02-07 CA CA3129270A patent/CA3129270A1/en active Pending
- 2020-02-07 EP EP20752195.6A patent/EP3920898B1/en active Active
- 2020-02-07 SG SG11202108225QA patent/SG11202108225QA/en unknown
- 2020-02-07 ES ES20752195T patent/ES3049086T3/es active Active
- 2020-02-07 MX MX2021009407A patent/MX2021009407A/es unknown
- 2020-02-07 CN CN202080026282.6A patent/CN113692277B/zh active Active
- 2020-02-07 WO PCT/US2020/017323 patent/WO2020163785A1/en not_active Ceased
- 2020-02-07 JP JP2021546285A patent/JP7705348B2/ja active Active
- 2020-02-07 AU AU2020219809A patent/AU2020219809B2/en active Active
- 2020-02-07 PH PH1/2021/551850A patent/PH12021551850A1/en unknown
- 2020-02-07 UA UAA202104441A patent/UA130366C2/uk unknown
- 2020-02-07 MY MYPI2021004502A patent/MY210043A/en unknown
- 2020-02-07 EA EA202192202A patent/EA202192202A1/ru unknown
- 2020-02-07 US US17/428,596 patent/US12558327B2/en active Active
-
2021
- 2021-07-28 IL IL285197A patent/IL285197A/en unknown
- 2021-08-04 MX MX2025004365A patent/MX2025004365A/es unknown
-
2025
- 2025-02-03 JP JP2025016270A patent/JP2025084754A/ja active Pending
- 2025-07-15 AU AU2025205464A patent/AU2025205464A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2025205464A1 (en) | 2025-07-31 |
| EP3920898C0 (en) | 2025-09-10 |
| JP2025084754A (ja) | 2025-06-03 |
| CN118557736A (zh) | 2024-08-30 |
| JP2022519721A (ja) | 2022-03-24 |
| CN113692277A (zh) | 2021-11-23 |
| US20220096401A1 (en) | 2022-03-31 |
| UA130366C2 (uk) | 2026-02-04 |
| WO2020163785A1 (en) | 2020-08-13 |
| EP4635514A2 (en) | 2025-10-22 |
| KR20210125507A (ko) | 2021-10-18 |
| AU2020219809A1 (en) | 2021-08-19 |
| BR112021015600A2 (pt) | 2021-10-05 |
| MY210043A (en) | 2025-08-22 |
| EA202192202A1 (ru) | 2021-11-03 |
| CN113692277B (zh) | 2024-07-16 |
| EP3920898B1 (en) | 2025-09-10 |
| MX2021009407A (es) | 2021-09-10 |
| AU2020219809B2 (en) | 2025-04-17 |
| EP3920898A1 (en) | 2021-12-15 |
| EP4635514A3 (en) | 2025-12-24 |
| JP7705348B2 (ja) | 2025-07-09 |
| PH12021551850A1 (en) | 2022-05-11 |
| MX2025004365A (es) | 2025-05-02 |
| US12558327B2 (en) | 2026-02-24 |
| SG11202108225QA (en) | 2021-08-30 |
| ES3049086T3 (en) | 2025-12-12 |
| EP3920898A4 (en) | 2022-11-09 |
| CA3129270A1 (en) | 2020-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201907158B (en) | Methods and compositions for treating sleep apnea | |
| IL276247A (en) | Methods and materials for the treatment of sleep apnea | |
| SG11202104158SA (en) | Composition and method for treating the lungs | |
| IL285197A (en) | Methods and preparations for the treatment of sleep apnea | |
| ZA202207394B (en) | Compositions and methods for treating hemoglobinopathies | |
| IL271503A (en) | Preparations and treatments for sleep disorders | |
| PL3253443T3 (pl) | Urządzenie do leczenia chrapania i bezdechu sennego | |
| SG11202013239RA (en) | Composition and method for treating pain | |
| IL285886A (en) | Preparations and methods for the treatment of laminopathy | |
| SG11202107325TA (en) | Methods and compositions for the treatment of fabry disease | |
| IL290348B1 (en) | Compositions and methods for surface treatment | |
| IL285796A (en) | Methods and preparations for the treatment of cancer | |
| IL280413A (en) | Bismuth-thiol preparations and wound treatment methods | |
| SG11202102442WA (en) | Methods and compositions for preventing and treating atherosclerosis and related diseases | |
| SG11202012055PA (en) | Methods and compositions for preventing or treating calciphylaxis | |
| PT3810128T (pt) | Composições para tratar e/ou prevenir doenças de agregação de proteinas | |
| IL304771A (en) | Preparations and methods for the treatment of a disease associated with dux4 overexpression | |
| EP3589344A4 (en) | SOUND ATTENUATION STRUCTURES AND METHODS FOR USE IN THE TREATMENT OF OBSTRUCTIVE SLEEP APNEA | |
| EP3720351A4 (en) | METHODS AND SYSTEMS FOR THE TREATMENT OF SLEEP APNEA | |
| IL288440A (en) | Materials and methods for the treatment of retinopathy | |
| IL307186A (en) | Methods and preparations for treating sleep apnea | |
| SG11202107355RA (en) | Improved method and compositions for surface treatment | |
| EP3624808A4 (en) | PROCEDURES AND COMPOSITIONS FOR IMPROVED SLEEP | |
| HK40059516A (en) | Methods and compositions for treating sleep apnea | |
| HK40041686A (en) | Compositions and methods for treating obstructive sleep apnea |